Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 January, 2022 17:51 IST
Dr. Reddy's launches Minoxidil for women for treatment of hair loss
Source: IRIS | 08 Sep, 2021, 05.00PM
Rating: NAN / 5 stars.
Comments  |  Post Comment


Dr Reddy's Laboratories, an integrated global pharmaceutical company, announced the launch of the prescription drug Minoxidil topical solution USP 2% and 5% for the treatment of female pattern hair loss (FPHL). Dr. Reddy's will sell its products under the brand names Mintop TM 2% and Mintop Eva 5% respectively.

The launch follows the first-ever approval of the additional indication by the Central Drugs Standard Control Organization (COSCO) in India for the use of Minoxidil topical solution USP 2% and 5% for treatment of FPHL.

Minoxidil topical solution will become available as first-line treatment option for FPHL in India. While Minoxidil topical solution has been approved in India for the treatment of alopecia in men (male pattern baldness), there are presently no other drugs approved for the treatment of FPHL in India.

Female pattern hair loss is the most common cause of hair loss in women and its prevalence increases with advancing age, often leading to psychological distress. Initial symptoms may develop during the teenage years and may lead to progressive hair loss with a characteristic pattern distribution. Prevalence of FPHL may also increase post menopause with a possible hormonal influence.

Minoxidil Topical Solution acts like a peripheral vasodilator that further enhances microcirculation to hair follicles. It can reverse the hair loss process of androgenetic alopecia by increasing the diameter of the hair shaft. The solution is responsible for stimulating anagen growth and prolonging the anagen phase. It also stimulates anagen recovery from the telogen phase.  Minoxidil will be available only on prescription by a dermatologist.

Shares of the company declined Rs 1.15, or 0.02%, to trade  at  Rs 4,901.25.  The total volume of shares traded is  23,508 at  the BSE (3.30 p.m, Wednesday).




 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
JSW Ispat Special Products reports consolidated net loss of Rs 28 crore in Q3 - 21-Jan-2022 19:49
Mphasis in collaboration with CrossTower - 21-Jan-2022 15:26
Asian Paints Q3FY22 Review-Inflation impacts profitability; outlook remains healthy - 21-Jan-2022 15:03
Hindustan Unilever Q3FY22 Review - Price/cost agility to address current underperformance - 21-Jan-2022 12:28
Bajaj Auto Q3FY22 Review- Exports hits all time high; Hold - 20-Jan-2022 17:19
IDBI Capital maintains Buy on CCL Products (India) - 20-Jan-2022 17:01
Karnataka Bank launches 'Online KYC updation' portal - 20-Jan-2022 13:22
Indian Hotels: When strategy meets execution! - 20-Jan-2022 12:43
Balu Forge acquires precision machining unit of Mercedes Benz Truck Factory in Germany - 19-Jan-2022 18:34
Ion Exchange secures contract worth Rs 1,370 mn from Numaligarh Refinery - 19-Jan-2022 15:53
CIL's supplies under e-auction log 31% growth during Apr-Dec'21 - 19-Jan-2022 15:09
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer